In patients with T-NHL, high RBMX expression was associated with non-response (resistant vs. sensitive: mean 185 vs. 127; p = 0.018; Figure 3a) and the area under the curve (AUC) was 0.725 (95% CI: 0.550–0.901; p = 0.012; Figure 3b) (specificity 66.7%, sensitivity 72.7%). The gene discussed is RBMX; the disease is non-Hodgkin lymphoma.